» Authors » Alexa Kupferschmitt

Alexa Kupferschmitt

Explore the profile of Alexa Kupferschmitt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 31
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Jobges M, Tempfli M, Kohl C, Herrmann C, Kelm S, Kupferschmitt A, et al.
Front Neurol . 2025 Jan; 15():1486751. PMID: 39835145
Background: Post COVID-19 condition (PCC) is increasingly recognized as a debilitating condition characterized by persistent symptoms following SARS-CoV-2 infection. Neuropsychological deficits, including cognitive impairments and fatigue, are prevalent in individuals...
2.
Kupferschmitt A, Jobges M, Randerath J, Hinterberger T, Loew T, Kollner V
J Psychosom Res . 2023 Nov; 175:111540. PMID: 37918327
Background: Depressive and cognitive symptoms like fatigue, loss of energy or sleep disorders characterise the post-COVID condition. Post-COVID psychosomatic rehabilitation should focus on both symptom groups. The current prospective cohort...
3.
Kupferschmitt A, Langheim E, Tuter H, Etzrodt F, Loew T, Kollner V
Front Rehabil Sci . 2023 Feb; 3:1093871. PMID: 36756465
Background: COVID-19 is associated with various symptoms and psychological involvement in the long term. In view of the multifactorial triggering and maintenance of the post-COVID syndrome, a multimodal therapy with...
4.
Kupferschmitt A, Hinterberger T, Montanari I, Gasche M, Hermann C, Jobges M, et al.
BMC Psychol . 2022 Jul; 10(1):189. PMID: 35906662
Background: In Patients suffering from post-COVID syndrome, in addition to physical limitations, cognitive limitations, fatigue, dyspnea as well as depression and anxiety disorders may also be present. Up to now...
5.
Kupferschmitt A, Etzrodt F, Kleinschmidt J, Kollner V
Psychother Psychosom Med Psychol . 2022 May; 73(1):34-41. PMID: 35605967
Currently (March 2022), more than 17 million people in Germany have been infected with the SARS-CoV-2 virus. It is expected that 5-10% of those infected will develop a clinically relevant...